Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy
|
Percutaneous Coronary Intervention Guidelines Microchapters |
|
PCI Approaches: |
|---|
|
CAD Revascularization: |
|
Pre-procedural Considerations: |
|
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
|
Quality and Performance Considerations: |
|
Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy On the Web |
|
American Roentgen Ray Society Images of Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy |
|
FDA on Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy |
|
CDC on Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy |
|
Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy in the news |
|
Blogs on Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy |
|
Directions to Hospitals Treating Percutaneous Coronary Intervention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)[1]
Post-Procedural Proton Pump Inhibitors and Anti-platelet Therapy (DO NOT EDIT)[1]
| Class I |
| "1. Proton pump inhibitors should be used in patients with a history of prior gastrointestinal bleeding who require dual antiplatelet therapy (DAPT).[2] (Level of Evidence: C)" |
| Class III (No Benefit) |
| "1. Routine use of a proton pump inhibitor is not recommended for patients at low risk of gastrointestinal bleeding, who have much less potential to benefit from prophylactic therapy.[2] (Level of Evidence: C)" |
| Class IIa |
| "1. Use of proton pump inhibitors is reasonable in patients with an increased risk of gastrointestinal bleeding (e.g., advanced age, concomitant use of warfarin, steroids, nonsteroidal antiinflammatory drugs, Helicobacter pylori infection) who require dual antiplatelet therapy (DAPT).[2] (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF (2010). "ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Journal of the American College of Cardiology. 56 (24): 2051–66. doi:10.1016/j.jacc.2010.09.010. PMID 21126648. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help)